Get started
Author

Luciana Messuti

Observed name: L. Messutti
OpenAlex ID: A5073209150
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy
2018 · Roberto Petrioli, Martina Chirra, et al. · Clinical Colorectal Cancer · 28
PDF
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study
2020 · Edoardo Francini, Fang-Shu Ou, et al. · Translational Oncology · 17
PDF
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study
2024 · Nicoletta Provinciali, Marco Piccininno, et al. · Reviews in Cardiovascular Medicine · 2
PDF
CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ).
2020 · Edoardo Francini, Fang-Shu Ou, et al. · Journal of Clinical Oncology
Registro osservazionale REGBEV: Analisi dei risultati clinici di Bevacizumab in combinazione con chemioterapia nella prima linea del carcinoma colon-retto metastico
2020 · Leonardo Gianluca Lacerenza, Lorenzo Laurenti, et al. · Giornale italiano di farmacia clinica
Il carcinoma polmonare non a piccole cellule trattato in seconda linea con il farmaco Nivolumab: analisi dei risultati clinici e della correlazione tra percentuale di espressione di PD-L1 e la risposta alla terapia. Registro Osservazionale REGNIVO
2019 · Leonardo Gianluca Lacerenza, Luciana Messuti, et al. · Giornale italiano di farmacia clinica
Eribulin vs. Eribulin + Bevacizumab in advanced-line treatment of Her-2 negative metastatic breast cancer
2016 · G. Rossi, I. Martellucci, et al. · Annals of Oncology
PDF
The complex management and treatment of hydatidiform mole: our experience
2016 · S. Marsili, G. Rossi, et al. · Annals of Oncology
Works count: 9
Citation count: 47
H-index: 2
I10-index: 2
Year
Topic
Type